Reunion Neuroscience expands Series A to $133m after positive trial milestones
The success of Reunion Neuroscience’s lead psychedelic candidate in a postpartum depression (PPD) trial has provided a last minute boost …
Post
-
-
European Society of Cardiology (ESC) Annual Meeting 2025
The European Society of Cardiology (ESC) Annual Meeting 2025, held from August 29 to September 1 in Madrid, Spain, showcased …
-
Novo Nordisk secures EMA approval for Rybelsus label update
Novo Nordisk has received the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approval for the …
-
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary …
-
Cadrenal Therapeutics acquires eXIthera’s Factor XIa inhibitors
Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals’ portfolio of Factor XIa inhibitors to expand its offerings in the anticoagulation market. Under the …
-
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal …
-
Podcast: How RWD Furthers Understanding of Pregnancy
This podcast explores how real-world data (RWD) fills gaps in understanding maternal and infant health, especially since pregnant individual often …
-
AstraZeneca halts £200m research investment in Cambridge
AstraZeneca has halted its planned £200m ($270m) investment in a research facility in Cambridge, UK, according to reports from Reuters. The …
-
FDA chief blames decades of regulatory failure for misleading pharma ads
The US Food and Drug Administration (FDA) commissioner Martin Makary has described the current state of direct-to-consumer pharmaceutical advertising as …
-
Amneal secures FDA approval for sodium oxybate solution
US-based Amneal Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its 500mg/mL sodium oxybate oral …
-
LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut
US-based biotech LB Pharmaceuticals has broken the 2025 biotech initial public offering (IPO) drought – and with style – raising …
-
Podcast: key trials and trends from ESC Congress 2025
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to …
-
AbbVie extends Rinvoq exclusivity by four years after generics settlements
AbbVie has bolstered the sales outlook of its blockbuster autoimmune drug Rinvoq (upadacitinib) by extending its exclusivity until 2037. The company …
-
Kashiv signs deal with CRISTÁLIA for Xolair biosimilar in LATAM
Kashiv BioSciences has entered a partnership with Brazilian biopharmaceutical firm CRISTÁLIA to facilitate the marketing of ADL-018/Omalizumab, a proposed biosimilar …
-
GTCR to acquire generic drug maker Zentiva
Czech producer of generic medications Zentiva is poised for a change in ownership as Advent has agreed to sell the …
